Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS REPORTS Q3 2018 RESULTS – Quarterly Revenues Eclipse $6.4 M

12 July 2018

Quebec City, Quebec, July 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the third quarter ended May 31, 2018. Highlights for the quarter Consolidated revenues reached $6,398,000 for the three-month period compared with $4,892,000 for the same period last year, an increase of $1,506,000 or 31%; Consolidated…

Read more

VISIT OPSENS AT THE CARDIOVASCULAR INNOVATIONS 2018 CONFERENCE

3 July 2018

Learn more about the benefits of OptoWire® as a workhorse wire at the Cardiovascular Innovations (CVI) 2018 Conference by visiting us at the Opsens booth (#T4) or attend the complimentary educational lunch symposium with live case transmission sponsored by Opsens. RSVP Now!  Educational Lunch Symposium “Beyond FFR – Optimal Tools and Techniques for Coronary Physiology 2018” Sponsored by…

Read more

VISIT OPSENS AT THE 14TH ANNUAL C3 CONFERENCE

4 June 2018

Learn more about the benefits of OptoWire as a workhorse wire at the 14th annual Complex Cardiovascular Catheter Therapeutics: Advanced Endovascular and Coronary Intervention Global Summit (C3) conference by visiting us at the Opsens booth #207 or attend the complimentary educational lunch symposium with live case transmission sponsored by Opsens. RSVP Now!  Live Case Educational Lunch Symposium “Beyond FFR…

Read more

OPSENS APPLAUDS JAPANESE GOVERNMENT NEW REGULATION SUPPORTING DIAGNOSIS, SUCH AS FFR, BEFORE TREATMENT OF CORONARY STENOSIS

24 April 2018

Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as a preferred assessment method. The MHLW recently revised medical…

Read more

OPSENS REPORTS Q2 2018 RESULTS – CONSOLIDATED PRODUCT SALES UP 44%

12 April 2018

Quebec City, Quebec, April 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter ended February 28, 2018. Highlights Consolidated product sales reached $5,352,000 compared with $3,710,000 for the same period last year, an increase of $1,642,000 or 44,3%; Fractional Flow Reserve (“FFR”) revenues reached $3,313,000…

Read more

OPSENS’ TECHNOLOGY GRANTED FDA APPROVAL IN ABIOMED’S IMPELLA CARDIAC PUMP®

3 April 2018

Quebec City, Quebec, April 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces that the integration of Opsens’ technology, within the Impella Cardiac Pump® (“Impella CP®“), marketed by its client Abiomed, Inc. (” Abiomed “), is approved by the US Food and Drug Administration (” FDA “). This news follows the US$6 million…

Read more

84th German Cardiac Society Annual Meeting in Mannheim 2018

30 March 2018

Opsens sponsored Symposium: Clinical value of FFR and adenosine-free alternatives in the cathlab Our Distributor, Bisping Medizintechnik GmbH will showcase the Opsens technology at German Cardiac Societies Annual Meeting in Mannheim, Germany, from April 4th to 7th, 2018. They will show the innovative, fast and easy-to-use OptoMonitor FFR system together with the best-in-class optical OptoWire…

Read more

VISIT OPSENS MEDICAL AT SCAI 2018

10 March 2018

Learn more about the benefits of OptoWire as a workhorse wire at the Society for Cardiovascular Angiography and Interventions – SCAI 2018 by visiting us at the Opsens booth (#603) or joining us at one of the following: Attend the Poster Session II, “Functional Optimization of Coronary Intervention Using Post-PCI Fractional Flow Reserve: A Prospective…

Read more

SIF 2018 – OPSENS MEDICAL ON EXHIBIT! March 21-24, 2018

27 February 2018

Hear, see and feel the OptoWire® Deux difference at SIF 2018 in Scottsdale, Arizona. Visit the Opsens Medical booth to meet the experts, experience an OptoWire demonstration, and learn more about The OptoWire® One-Wire PCI™ Program!

ATTEND THE OPSENS MEDICAL SPONSORED SYMPOSIUM AT THE CRT 2018 CONFERENCE

19 February 2018

Attend the Opsens sponsored complimentary lunch educational symposium, “Upgrading Coronary Physiologic Approaches: Methods, Myths, and Best Practices” at CRT (Cardiovascular Research Technologies) 2018 Conference in Washington, DC. Opsens offers the first fiber-optic FFR guidewire with nitinol core, providing superior handling, functionality and accuracy, particularly beneficial in complex PCI. Leading experts in coronary physiology will demonstrate clinical utility…

Read more